Prevalence and significance of subcentimeter hepatic lesions in patients with localized pancreatic adenocarcinoma

Por Elnahal, Shereef M., Shinagare, Atul B., Szymonifka, Jackie, Hong, Theodore S., Enzinger, Peter C., Mamon, Harvey J.
Publicado no Pract Radiat Oncol (2012)

Impact of Hospital Volume on Recurrence and Survival After Surgery for Gastric Cancer

Por Enzinger, Peter C., Benedetti, Jacqueline K., Meyerhardt, Jeffrey A., McCoy, Sheryl, Hundahl, Scott A., Macdonald, John S., Fuchs, Charles S.
Publicado em 2007

Identification of Potentially Avoidable Hospitalizations in Patients With GI Cancer

Por Brooks, Gabriel A., Abrams, Thomas A., Meyerhardt, Jeffrey A., Enzinger, Peter C., Sommer, Karen, Dalby, Carole K., Uno, Hajime, Jacobson, Joseph O., Fuchs, Charles S., Schrag, Deborah
Publicado em 2014

Randomized Phase II Study of Gemcitabine Administered at a Fixed Dose Rate or in Combination With Cisplatin, Docetaxel, or Irinotecan in Patients With Metastatic Pancreatic Cancer:...

Por Kulke, Matthew H., Tempero, Margaret A., Niedzwiecki, Donna, Hollis, Donna R., Kindler, Hedy L., Cusnir, Michael, Enzinger, Peter C., Gorsch, Stefan M., Goldberg, Richard M., Mayer, Robert J.
Publicado em 2009

O(6)-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors

Por Kulke, Matthew H., Hornick, Jason L., Frauenhoffer, Christine, Hooshmand, Susanne, Ryan, David P., Enzinger, Peter C., Meyerhardt, Jeffrey A., Clark, Jeffrey W., Stuart, Keith, Fuchs, Charles S., Redston, Mark S.
Publicado em 2009

Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer

Por Wolpin, Brian M., Hezel, Aram F., Abrams, Thomas, Blaszkowsky, Lawrence S., Meyerhardt, Jeffrey A., Chan, Jennifer A., Enzinger, Peter C., Allen, Brittany, Clark, Jeffrey W., Ryan, David P., Fuchs, Charles S.
Publicado em 2009

Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors

Por Chan, Jennifer A., Stuart, Keith, Earle, Craig C., Clark, Jeffrey W., Bhargava, Pankaj, Miksad, Rebecca, Blaszkowsky, Lawrence, Enzinger, Peter C., Meyerhardt, Jeffrey A., Zheng, Hui, Fuchs, Charles S., Kulke, Matthew H.
Publicado no J Clin Oncol (2012)

A Phase 2 Study of Oral MKC-1 in Patients with Unresectable or Metastatic Pancreatic Cancer

Por Faris, Jason E., Arnott, Jamie, Zheng, Hui, Ryan, David P., Abrams, Thomas A., Blaszkowsky, Lawrence S., Clark, Jeffrey W., Enzinger, Peter C., Hezel, Aram F., Ng, Kimmie, Wolpin, Brian M., Kwak, Eunice L.
Publicado em 2011

CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers

Por Enzinger, Peter C., Burtness, Barbara Ann, Niedzwiecki, Donna, Ye, Xing, Douglas, Kathe, Ilson, David H., Villaflor, Victoria Meucci, Cohen, Steven J., Mayer, Robert J., Venook, Alan, Benson, Al Bowen, Goldberg, Richard M.
Publicado no J Clin Oncol (2016)

Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer

Por Meyerhardt, Jeffrey A., Ancukiewicz, Marek, Abrams, Thomas A., Schrag, Deborah, Enzinger, Peter C., Chan, Jennifer A., Kulke, Matthew H., Wolpin, Brian M., Goldstein, Michael, Blaszkowsky, Lawrence, Zhu, Andrew X., Elliott, Meaghan, Regan, Eileen, Jain, Rakesh K., Duda, Dan G.
Publicado em 2012

Preoperative Cetuximab, Irinotecan, Cisplatin, and Radiation Therapy for Patients With Locally Advanced Esophageal Cancer

Por Lee, Michael S., Mamon, Harvey J., Hong, Theodore S., Choi, Noah C., Fidias, Panagiotis M., Kwak, Eunice L., Meyerhardt, Jeffrey A., Ryan, David P., Bueno, Raphael, Donahue, Dean M., Jaklitsch, Michael T., Lanuti, Michael, Rattner, David W., Fuchs, Charles S., Enzinger, Peter C.
Publicado em 2013

Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma

Por Wolpin, Brian M., Rubinson, Douglas A., Wang, Xiaoxu, Chan, Jennifer A., Cleary, James M., Enzinger, Peter C., Fuchs, Charles S., McCleary, Nadine J., Meyerhardt, Jeffrey A., Ng, Kimmie, Schrag, Deborah, Sikora, Allison L., Spicer, Beverly A., Killion, Leah, Mamon, Harvey, Kimmelman, Alec C.
Publicado em 2014

Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer

Por Cleary, James M., Mamon, Harvey J., Szymonifka, Jackie, Bueno, Raphael, Choi, Noah, Donahue, Dean M., Fidias, Panos M., Gaissert, Henning A., Jaklitsch, Michael T., Kulke, Matthew H., Lynch, Thomas P., Mentzer, Steven J., Meyerhardt, Jeffrey A., Swanson, Richard S., Wain, John, Fuchs, Charles S., Enzinger, Peter C.
Publicado no BMC Cancer (2016)

Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer

Por Wolpin, Brian M., Ng, Kimmie, Zhu, Andrew X., Abrams, Thomas, Enzinger, Peter C., McCleary, Nadine J., Schrag, Deborah, Kwak, Eunice L., Allen, Jill N., Bhargava, Pankaj, Chan, Jennifer A., Goessling, Wolfram, Blaszkowsky, Lawrence S., Supko, Jeffrey G., Elliot, Meaghan, Sato, Kaori, Regan, Eileen, Meyerhardt, Jeffrey A., Fuchs, Charles S.
Publicado em 2013

Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

Por Zhu, Andrew X., Sahani, Dushyant V., Duda, Dan G., di Tomaso, Emmanuelle, Ancukiewicz, Marek, Catalano, Onofrio A., Sindhwani, Vivek, Blaszkowsky, Lawrence S., Yoon, Sam S., Lahdenranta, Johanna, Bhargava, Pankaj, Meyerhardt, Jeffrey, Clark, Jeffrey W., Kwak, Eunice L., Hezel, Aram F., Miksad, Rebecca, Abrams, Thomas A., Enzinger, Peter C., Fuchs, Charles S., Ryan, David P., Jain, Rakesh K.
Publicado em 2009